Children with osteogenesis imperfecta are often treated with intraenous bisphosphonates. We aimed to assess thesafety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

ADAMI, Silvano;
2013-01-01

Abstract

Children with osteogenesis imperfecta are often treated with intraenous bisphosphonates. We aimed to assess thesafety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.
2013
risedronate; osteogenesis imperfecta
File in questo prodotto:
File Dimensione Formato  
Bishop, Lancet, 2013.pdf

non disponibili

Descrizione: articolo
Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 516.02 kB
Formato Adobe PDF
516.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/635155
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 148
  • ???jsp.display-item.citation.isi??? 133
social impact